NCT05716100Phase 3Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-01Estimated
Enrollment · participants360Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Oct 2026. After: Jan 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview